Format

Send to

Choose Destination
Br J Clin Pharmacol. 2009 Jul;68(1):116-9. doi: 10.1111/j.1365-2125.2009.03430.x.

Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.

Author information

1
Tibotec Inc., 1020 Stony Hill Road, Yardley, PA 19067, USA. vsekar@tibus.jnj.com

Abstract

AIM:

To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infected patients.

METHODS:

An open-label, randomized, crossover study. Patients received Treatment A [NVP 200 mg b.i.d. plus > or =2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)] and Treatment B [A plus DRV/r 300/100 mg b.i.d. (DRV oral solution)] or Treatment B2 [A plus DRV/r 400/100 mg b.i.d. (DRV tablet)] in two 14-day sessions.

RESULTS:

Mean NVP AUC(12h) increased by 27% [least square means ratio 1.27 (95% confidence interval 1.02, 1.58)]. Mean DRV and ritonavir exposures were similar to historical data. Co-administration was well tolerated.

CONCLUSIONS:

DRV/r and NVP have no clinically relevant interaction. No dose adjustments are required.

PMID:
19660009
PMCID:
PMC2732946
DOI:
10.1111/j.1365-2125.2009.03430.x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center